| Sep 29 |
BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
|
| Sep 17 |
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
|
| Sep 12 |
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
|
| Sep 6 |
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
|
| Sep 5 |
BioCryst Pharmaceuticals names Donald Fong as chief medical officer
|
| Sep 5 |
BioCryst Appoints Dr. Donald Fong Chief Medical Officer
|
| Aug 29 |
High Growth Tech Stocks To Watch In August 2024
|
| Aug 22 |
BioCryst to Present at Upcoming Investor Conferences
|
| Aug 10 |
Piper lists eight defensive biotechs to face market volatility
|
| Aug 5 |
BioCryst up 8% after raising 2024 Orladeyo revenue guidance
|
